Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Trial Profile

Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti MUC1 CAR T cell/PD-1 knockout engineered T cell therapy Guangzhou Anjie Biomedical Technology (Primary) ; Anti-MUC1 CAR-T cell therapy; PD-1 knockout T-cells
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2023 Results (n=9) reporting efficacy and safety data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jul 2021 Results(n=8) cutoff date (February 11, 2021) assessing safety and efficacy of PD-1 knockout engineered anti-MUC1 CART cells in the treatment of patients with advanced oesophageal cancer presented at the 23rd World Congress on Gastrointestinal Cancer
    • 25 Oct 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top